GlassScriptPhysician profile
Chad Nathaniel Wood
NPI 1477646875
$1,175.29
in general payments reported to CMS, 2019-2025
19 companies · $328 in 2025
The $328 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $324 · 2024: $523 · 2025: $328.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,175.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $172.55 | 2023-2025 | Qulipta |
| Corcept Therapeutics | $157.66 | 2024-2025 | Korlym |
| Novo Nordisk INC | $151.31 | 2023-2024 | Ozempic, Rybelsus |
| Boston Scientific Corporation | $125.31 | 2023-2025 | Watchman Flx, Wavewriter Alpha Prime 16 |
| Glaxosmithkline, LLC. | $125.00 | 2023 | Arexvy |
| Alkermes, INC. | $73.10 | 2024 | Vivitrol |
| Merck Sharp & Dohme LLC | $66.79 | 2023 | Verquvo |
| Inspire Medical Systems, INC. | $59.95 | 2024 | Inspire |
| Pfizer INC. | $31.73 | 2023 | |
| Cranial Technologies, INC | $30.26 | 2023-2024 | Doc Band |
| Indivior INC. | $28.16 | 2025 | Sublocade |
| Astellas Pharma US INC | $22.13 | 2025 | Veozah |
| Seqirus USA INC | $20.55 | 2025 | Fluad, Flucelvax |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.79 | 2024 | Jardiance |
| Janssen Pharmaceuticals, INC | $19.78 | 2023 | Spravato |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $19.65 | 2025 | Breztri |
| Dexcom, INC. | $19.29 | 2025 | Dexcom G6 Transmitter |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.90 | 2025 | Caplyta |
| Lilly USA, LLC | $13.38 | 2023 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chad Wood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.